Login
Skye Bioscience, Inc. logo

Skye Bioscience, Inc.

skyebioscience.com

What Do They Do?

Develops antibody drug candidates for people with obesity, overweight and metabolic disorders, led by nimacimab, which targets a receptor involved in metabolic regulation.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$12.8M in Q3 FY2025
  • Sep 8, 2026 Chief Financial Officer John Sharp resigned CEO Punit Dhillon took on the principal financial and accounting officer role.
  • Aug 12, 2026 Agreed to acquire Redx Pharma in a proposed transaction Skye said it would discontinue the CBeyond trial and pause nimacimab development.

From eye treatments to metabolic disease The earlier report centered on synthetic cannabinoid derivatives and an ophthalmic treatment for glaucoma and ocular hypertension. The latest report centers on nimacimab for obesity and metabolic disorders and says the ocular program was eliminated.

Who Do They Compete With?

Competes with Novo Nordisk, Eli Lilly, Structure Therapeutics, and Viking Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support